anonymous
Guest
anonymous
Guest
Has anyone heard any details about the new trauma comp plan? 9% base w a massive growth number was what I was told
So have we confirmed it’s being cut to 9%?
9% w 22% growth carrot. Sorry losers, no more getting paid to just cover cases. Of course this was going to happen!
Is this really true on the comp plan? With this comp plan your growth rate would have to increase every year to make more than the old comp plan. In an age of pricing pressures, this is impossible. JnJ wins in long run as cost to sales continues to decrease. I feel they just look for ways to drop rep income gradually over time. No wonder every decent rep leaves
Comp plan is not significantly changing. Like all companies, the comp plan is evaluated this time of year to be the most competitive in the medical device business and we will continue to pay sales reps market rate and market leading compensation. You'll get an email from me very soon but until then please stay focused on closing out a successful 2019 sales year. Thank you,
HAHAHAH! I wouldnt be surprised if they did send an email like this.
It’s not significantly changing, just moving from 11% to 9%....just like when it was 12.5% to 11%. Super simple
My manager told me that I shouldn’t worry too much. Since they are trying to build cmf back up, significant comp changes are unlikely bc they can’t afford to lose any more reps to the competition. I was told that if growth can’t be achieved within the next 12 months or so, comp will change drastically and managers could be under a scary/serious reorganization. I get worn out on all the changes JnJ makes every year. I miss the boring, stable days of Synthes. What a fantastic company. I wish Hansjorg didn’t sell to JnJ. Now it’s a total shit show